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Although one of the latter sections, a number of interestingconcepts and ideas came out of the radiation oncology
talks at IASLC 2011 in Santa Monica. The session was
chaired by Everett Vokes of the University of Chicago and by
Dr. David Johnson of UT Southwestern Medical Center at
Dallas. The four speakers in order were Hak Choy of UT
Southwestern Medical Center at Dallas, Michael O’Reilly
from UT MD Anderson Cancer Center, Walter Curran of
Emory University Medical Center, and Everett Vokes of the
University of Chicago. The following summaries highlight
the main themes of each talk and attempt to provide a
framework for their critical importance to the clinical and
biologic aspects of radiation oncology.
Summaries of Talks
The first talk, by Hak Choy, focused on combination
therapies in the setting of Stereotactic Ablative Radiation
(SABR). One of the recent important findings out of the
radiation biology laboratories at UT Southwestern Medical
Center (Chaitin Nirodi—–both published and unpublished
data) is the notion that EGFR mutant status goes far in
potentially determining how sensitive non-small cell lung
cancer (NSCLC) cells are to radiation therapy.1,2 With an
increasing emphasis on demonstrating that EGFR is in-
volved in DNA repair along with its function as a modu-
lator of mitogenic signals, it has become imperative to
understand how mutant EGFR lung tumor cells may be-
have in unique ways. Nirodi’s laboratory has shown that
mutant EGFR cells are more sensitive to external beam
radiation in comparison with wild-type EGFR tumor cells.
This may be occurring because wild-type EGFR tumor
cells may have some continued DNA repair capacity ren-
dering them somewhat radiation resistant. On the contrary,
mutant EGFR cells, acting similarly to cells treated with
cetuximab, have less DNA repair capacity because of the
lost EGFR function, and as a result, tend to respond to
radiation effects.
Initially in his talk, Dr. Choy summarized what SABR
is and described outcomes from the 2010 JAMA article
demonstrating benefits of using SABR in inoperable patients
with stage I/II NSCLC in a phase II study.3 Subsequently, he
provided a summary of the orthotopic lung tumor models
available for mice and rats with an emphasis on UT South-
western Medical Center’s capacity to irradiate tumors at
stereotactic doses with image guidance. He then went on to
mention how SABR plus DNA PKC inhibitors in combina-
tion are more effective in promoting cell death when com-
pared with fractionated radiation plus or minus these same
inhibitors in preclinical evaluations. When combining SABR
with EGFR inhibitors including cetuximab, the effects were
most profound in lung tumor cell lines with mutant EGFR
expression. It thus becomes more and more imperative to
understand the nature of the EGFR mutations present in
NSCLCs before deciding on optimal treatment approaches.
Cetuximab’s utility in the setting of combined modality
therapy with radiation is highly dependent on not simply
EGFR overexpression, but whether that overexpression is
in the wild-type or mutant form. Ultimately, combining
SABR with EGFR inhibitors for tumor cells overexpress-
ing specific mutant EGFR forms maybe the most syner-
gistic combination.
Michael O’Reilly expounded on another aspect of con-
current chemoradiation approaches, the use of antiangiogenic
modulators and fractionated radiation. Over several years, the
O’Reilly group has worked on multiple orthotopic mouse
models to study radiation combined with angiogenesis inhib-
itors.4 With respect to NSCLC, he presented preclinical data
showing that cediranib works best when given with fraction-
ated chemoradiation to block locoregional lung tumor spread
to the mediastinum and distant spread. This block in angio-
genesis leads to increased tumor apoptosis but no obvious
difference in tumor or endothelial proliferative capacity. With
respect to preclinical small cell lung cancer (SCLC) studies,
combined use of doublet chemotherapy with fractionated
radiation and cediranib or vandetanib led to increased tumor
control but limited control of metastatic disease in the ab-
sence of cediranib. Finally, there was discussion of the
toxicity associated with combined modality treatment in the
thorax, specifically the elevated rate of tracheoesophageal
fistulas in the setting of chemoradiation with avastin. A point
was made that with the use of newer technologies, including
proton radiation therapy and better image guidance, fewer of
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these events may occur when combining angiogenesis inhib-
itors with radiation and cytotoxic agents.
The concept of the next talk, by Walter Curran, was to
describe the latest clinical advances with radiation and EGFR
inhibitors/TKIs (tyrosine kinase inhibitors). Dr. Curran di-
vided his talk into five sections—preclinical evidence or lack
thereof for using TKIs with radiation, sequential chemoradia-
tion-TKI trial results, concurrent chemoradiation-TKI results,
possible role for these combinations in lower performance
status patients, and combining TKIs with hypofractionation/
SABR. Several preclinical studies using TKIs with radiation
previously showed great synergy in effectuating NSCLC cell
kill as far back as 2003. In subsequent sequential clinical
trials including SWOG 0023 attempting to take advantage of
this preclinical work, it was summarized that when compar-
ing chemoradiation plus taxanes plus either gefitinib or pla-
cebo, the group receiving gefitinib had worse survival out-
comes with increased toxicity.5 When randomizing patients
with NSCLC after chemoradiation straight to adjuvant erlo-
tinib versus placebo, there were no differences in outcome.
There were till recently several ongoing concurrent
trials including a phase I study at the University of Colorado
and CALGB 30106 which were looking at induction chemo-
therapy (with gefitinib) followed by concurrent chemoradia-
tion with gefitinib given throughout primary therapy and as
maintenance for stage III NSCLC patients. The former study
was discontinued because of the negative results of SWOG
0023. The 1-year overall survival (OS) for the latter study
was 60%.6 An Australian phase I/II study for stage III
NSCLC patients has been evaluating increasing doses of
paclitaxel with concurrent radiation plus ZD1839 and has
shown a 3-year overall survival of 60% (Ball et al, ASCO
2007). A similar study at UNC has been evaluating induction
chemotherapy followed by concurrent chemoradiation plus
daily gefitinib with a dose escalation to 74 Gy.7 Unfortu-
nately, the median survival time (MST) for this study has
been 16 months. Another phase I study by Choong et al.8 has
examined cisplatin/etoposide-based chemoradiation plus er-
lotinib and docetaxel consolidation to carboplatin/taxol-based
induction followed by chemoradiation plus erlotinib and
found no significant differences in outcomes from historical
results. Study LCCC 0511 which is evaluating bevacizumab
and erlotinib with induction and concurrent carbotaxol with
74 Gy thoracic radiation is still in accrual stage.
Finally, two other studies combining EGFR inhibtors/
TKIs were described. CALGB 30605/RTOG 0972 looks at
lower performance status patients and gives them induction
carboplatin and abraxane followed by Erlotinib  66 Gy
thoracic radiation. This study is still accruing. Finally, a study
submitted to CTEP is comparing standard fractionation radi-
ation versus hypofractionation with TKIs. Ultimately, the
jury is still out on combining EGFR TKIs with concurrent
therapy. The early studies showed no benefit but the newer
studies are yet to finish accruing.
The final talk of the session was by Everett Vokes who
summarized clinical studies evaluating the roles of various
radiation sensitizers. As per Dr. Vokes, the current highly
relevant questions for stage III NSCLC include the sequenc-
ing, cycle number, and integration of systemic agents includ-
ing targeted therapies with radiation. He started by describing
combining pemetrexed, a potent antimetabolite, with concur-
rent radiation. He reinforced the notion that there is ample
preclinical evidence which led to the supporting of pem-
etrexed in its relevance to multiple clinical trials. A phase I
study from 2001 involved a dose escalation with pemetrexed
and concurrent radiation for stage III NSCLC with no in-
creased toxicity.9 A CALGB phase II study with chemora-
diation using pemetrexed plus carboplatin versus cisplatin has
no new updates. CALGB 30407 compared carboplatin/pem-
etrexed/radiation with that same regimen plus cetuximab
followed by more pemetrexed. A majority of patients were
able to receive some maintenance cycles of chemotherapy
with pemetrexed after the initial definitive treatment. The
primary grades 3 to 4 hematologic toxicities similar in both
arms were neutropenia and thrombocytopenia. There were
4% treatment-related deaths in each arm. Median OS was
21.2 months in the first arm and 22.4 months in the second
arm. On subset analyses by histology, there was no difference
in response or outcomes when comparing squamous or nons-
quamous pathology. Finally, there was some description of
the PROCLAIM study, in which one arm of patients will
receive cisplatin/pemetrexed/radiation followed by pem-
etrexed  4 cycles versus cisplatin/etoposide/radiation fol-
lowed by a platinum doublet. The talk concluded with dis-
cussion of this study’s continued accrual marks.
Future Directions
In general, this session highlighted the need for better
combined modality therapy in the face of continued poor
outcomes for stage III NSCLC. Several of the studies high-
lighted the role of targeting specific pathways in conjunction
with either fractionated or stereotactic radiation in the hopes
of optimizing loco-regional responses. A better selection of
patients for the EGFR inhibitor studies based on molecular
tumor profiles in conjunction with SABR may prove most
efficacious.
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